Home > Healthcare & Medical Devices > U.S. Home Infusion Therapy Market
U.S. Home Infusion Therapy Market size surpassed USD 11 billion in 2022 and is poised to depict over 10% CAGR through 2023-2032. This is a result of the increasing influx of chronic disease patients and high healthcare costs.
To get more details on this report: Request Free Sample PDF
Chronic diseases continue to impact individual lifestyles and accelerate the use of medications and other diagnostic procedures. Over the years, the population of patients diagnosed with chronic conditions such as asthma, cancer, and chronic obstructive pulmonary disease, among others, has surged. Based on data from the Asthma and Allergy Foundation of America, in 2021, close to 20.4 million adults were diagnosed with asthma across the U.S. To reduce healthcare costs, asthma patients are relying on at-home infusion therapies to prevent airway inflammation.
Report Coverage | Details |
---|---|
Base Year: | 2022 |
Market Size in 2022: | USD 11 Billion |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 10% |
2032 Value Projection: | USD 29 Billion |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 254 |
Tables, Charts & Figures: | 300 |
Segments covered: | Product, Application, and Zone |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
To get more details on this report: Request Free Sample PDF
Safety concerns and risks of complications associated with home infusion care may, however, assert a negative impact on industry development to a certain extent. For example, the U.S. FDA reported several issues, such as software defects, damaged mechanical parts, inadequate user interface design, and battery failures, associated with infusion pump sets. Despite these challenges, the steadily increasing number of patients with chronic ailments such as Crohn’s disease and ulcerative colitis will create lucrative growth opportunities for home infusion therapy service providers in the U.S.
To get more details on this report: Request Free Sample PDF
U.S. home infusion therapy market from the infusion pumps product segment will be valued at USD 14 billion by 2032, owing to the growing burden of diabetes in the United States. Devices such as infusion pumps have emerged as preferred care products for diabetes treatment since they can deliver insulin, nutrients, antibiotics, and other fluids in controlled amounts. These benefits, alongside the steady rise in diabetes prevalence, are thus likely to augment service consumption for the controlled administration of medications in diabetic patients.
To get more details on this report: Request Free Sample PDF
U.S. home infusion therapy market from the anti-infective application segment is poised to depict more than 9.5% CAGR through 2032. This is credited to the rising prevalence of various infectious diseases, including pneumonia, chronic urinary tract infections, cellulitis, catheter sepsis, and abscesses. Most of these patients are opting for anti-infective therapy using infusion devices in homecare facilities, given the product’s ability to be safely managed during diagnosis and treatment. The effectiveness of anti-infective therapy in chronic disease diagnosis and treatment will therefore spur home infusion service adoption in the United States.
South Atlantic home infusion therapy market size is anticipated to be worth over USD 6 billion by 2032, on account of the high incidence rate of Alzheimer's disease among older adults. This increase in the Alzheimer’s patient population has increased the adoption of treatments such as home enteral nutrition therapy. Additionally, the increasing per capita income and the prevalence of chronic diseases will accelerate the development of at-home infusion therapy across the region.
B. Braun Melsungen AG, Baxter International Inc., Fresenius Kabi, Contec Medical Systems Co. Ltd, Becton Dickinson and Company, Terumo Corporation, ICU Medical Inc., Erenler Medikal, Moog Inc., Amsino International, Inc., Lepu Medical Technology, and JMS Co. Ltd. are some of the key players in the market. These firms are focusing on mergers & acquisitions, among other strategies to reinforce their foothold in the regional market.
Since the onset of the COVID-19 pandemic, there has been a significant shift in patient preference toward disease diagnosis and treatment in homecare facilities, to curb the risk of hospital-acquired infections. The heavy inflow of patients with hypertension is also observed following the outbreak.
Since home infusion therapy is commonly prescribed in the treatment of such ailments, these factors are likely to increase the reliance on at-home subcutaneous and intravenous options to treat pulmonary hypertension. The COVID-19-induced pressure on healthcare facilities in the U.S. has also augmented the demand for home nutritional infusion therapies to diagnose diseases in home settings, without having to visit hospitals. Factors such as these are thus likely to influence market expansion.
The U.S. home infusion therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments: Click here to Buy Section of this Report
By Product
By Application
The above information is provided for the following zones and states: